Trial
NCT06395090
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Neoplasm Metastasis
Intervention
Pembrolizumab
Why stopped
development program discontinuation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-08